Corporate Finance, DeFi, Blockchain, Web3 News
Fintech, DeFi, Blockchain, Web3 Daily News by Finyear

ImClone nomme Kenneth J. Zuerblis CFO

( - La société américaine de biotechnologies ImClone Systems annonce la nomination de Kenneth Zuerblis au poste de CFO et de Senior Vice President, avec prise d'effet au 31 mars 2008.

ImClone nomme Kenneth J. Zuerblis CFO
La société précise que Kenneth Zuerblis est mieux connu dans le secteur des biotechnologies pour avoir occupé pendant 11 ans les fonctions de CFO chez Enzon Pharmaceuticals, société de biopharmacie cotée sur le Nasdaq.

© Copyright CFO-news

Communiqué original :

ImClone Appoints Kenneth J. Zuerblis Chief Financial Officer

ImClone Systems Incorporated (NASDAQ: IMCL), a global leader in the development and commercialization of novel antibodies to treat cancer, today announced that it has appointed Kenneth J. Zuerblis as Senior Vice President and Chief Financial Officer, effective March 31, 2008.

Mr. Zuerblis, age 49, brings to ImClone more than 25 years of financial and operational management experience. Mr. Zuerblis is best known within the biotechnology industry as a former Chief Financial Officer of Nasdaq-traded Enzon Pharmaceuticals, Inc., a biopharmaceutical company focused on the treatment of cancer and other life-threatening conditions. During his eleven-year tenure as Enzon's Chief Financial Officer, the company successfully transitioned from a small, royalty-based specialty pharmaceutical organization into a fully integrated biopharmaceutical company with significant revenues driven by five marketed products and substantial capabilities in research, development, manufacturing, sales and marketing.

"Ken brings to ImClone a valuable combination of strategic, financial, operational and public company experience as well as a strong commitment to the development of new treatment options for cancer," said John H. Johnson, Chief Executive Officer of ImClone. "He has an impressive track record in growing a development-stage organization into a profitable multi-product biopharmaceutical company. We believe Ken will contribute substantially to ImClone's efforts in becoming a fully-integrated global leader in cancer therapies as we continue to aggressively pursue initiatives to maximize our ERBITUX(R) franchise and further advance our robust pipeline of novel antibodies."

Mr. Zuerblis joined Enzon in 1991 and served as its Chief Financial Officer from 1994 to 2005. At Enzon, he oversaw all of the company's finance, accounting and investor relations activities, as well as information technologies and other operational areas. Notably, during Mr. Zuerblis' tenure, Enzon expanded its proprietary pipeline, established significant revenues from five marketed products, and achieved profitability and positive cash flows.

"Joining ImClone at this stage in its transformation to a global multi-product biopharmaceutical company is a tremendous opportunity," said Mr. Zuerblis. "I look forward to working with John and the team to execute on our strategy to grow the company and build shareholder value."

Prior to joining Enzon, Mr. Zuerblis was at KPMG LLP where he held positions of increasing responsibility over a ten-year period, serving in various advisory roles, including strategic business, tax, audit, and debt and equity financings. Mr. Zuerblis is a certified public accountant and has a degree in accounting from Seton Hall University.

About ImClone Systems
ImClone Systems Incorporated is a fully integrated biopharmaceutical company committed to advancing oncology care by developing and commercializing a portfolio of targeted biologic treatments designed to address the medical needs of patients with a variety of cancers. The Company's research and development programs include growth factor blockers and angiogenesis inhibitors. ImClone Systems' headquarters and research operations are located in New York City, with additional administration and manufacturing facilities in Branchburg, New Jersey.

ERBITUX is a registered trademark of ImClone Systems Incorporated.

Mardi 22 Avril 2008